PXMD Stock Price, PaxMedica, Inc. Quote, Chart

Market Summary

USD0.240.00

Delayed

0.00%

PXMD Stock Price

View Fullscreen

PXMD RSI Chart

PXMD Valuation

Market Cap

1.9M

Price/Earnings (Trailing)

-0.1

Price/Free Cashflow

-0.17

PXMD Price/Earnings (Trailing)

PXMD Profitability

Return on Equity

-1.5K%

Return on Assets

-627.56%

Free Cashflow Yield

-582.98%

PXMD Fundamentals

PXMD Earnings

Earnings (TTM)

-18.2M

Earnings Growth (Yr)

3.49%

Earnings Growth (Qtr)

37.5%

Breaking Down PXMD Revenue

Last 7 days

14.3%

Last 30 days

-70%

Last 90 days

-63.6%

How does PXMD drawdown profile look like?

PXMD Financial Health

Current Ratio

2.4

PXMD Investor Care

Shares Dilution (1Y)

804.67%

Diluted EPS (TTM)

-6.4

Tracking the Latest Insider Buys and Sells of PaxMedica, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	weisman howard j.	sold (taxes)	-2,019	0.69	-2,927	chief executive officer
Mar 12, 2024	coelho john f	sold (taxes)	-142	0.69	-207	-
Mar 12, 2024	casamento charles j	sold (taxes)	-684	0.69	-992	-
Mar 12, 2024	hough david w.	sold (taxes)	-1,001	0.69	-1,452	chief medical officer
Mar 12, 2024	sheldon stephen	sold (taxes)	-2,315	0.69	-3,356	cfo and coo
Mar 12, 2024	larochelle karen	sold (taxes)	-416	0.69	-604	-
Mar 12, 2024	rome zachary	sold (taxes)	-3,383	0.69	-4,904	-
Feb 21, 2024	hough david w.	sold (taxes)	-191	0.659	-291	chief medical officer
Feb 21, 2024	sheldon stephen	sold (taxes)	-160	0.659	-243	cfo and coo
Jan 29, 2024	casamento charles j	sold (taxes)	-73.72	0.76	-97.00	-

Which funds bought or sold PXMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-21,176	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	47.93	-29.00	8,410	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	4.09	-1,525	3,582	-%
May 14, 2024	Clearstead Advisors, LLC	reduced	-99.96	-1,698	1.00	-%
May 13, 2024	UBS Group AG	sold off	-100	-372	-	-%
May 10, 2024	JPMORGAN CHASE & CO	sold off	-100	-4,314	-	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	3.45	-13.00	30.00	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	1,400	13.00	15.00	-%
May 08, 2024	Souders Financial Advisors	new	-	20,400	20,400	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	13,306	13,306	-%

Are Funds Buying or Selling PXMD?

Are funds buying PXMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PXMD

No. of Funds

Unveiling PaxMedica, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	lind global fund ii lp	9.9%	251,770	SC 13G/A
Nov 29, 2023	lind global fund ii lp	9.9%	450,000	SC 13G

Recent SEC filings of PaxMedica, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 11, 2024	8-K	Current Report
Apr 03, 2024	PRE 14A	PRE 14A
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to PaxMedica, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

PaxMedica, Inc. News

Latest updates

PaxMedica, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-49.1%	2,893	5,680	3,234	5,144	4,752	2,204	5,980	556	603	649	1,124
Current Assets	-49.1%	2,893	5,680	3,234	5,144	4,752	2,204	5,980	9.00	-	444	1,124
Cash Equivalents	-65.5%	1,627	4,711	1,153	3,070	3,986	1,902	5,563	9.00	49.00	444	1,124
Liabilities	-25.8%	1,703	2,295	3,770	2,879	2,220	2,096	3,591	8,453	9,605	10,758	5,752
Current Liabilities	-33.0%	1,203	1,795	3,270	2,425	1,799	2,096	3,591	8,453	-	10,758	5,752
Shareholder's Equity	-64.8%	1,190	3,385	-	2,265	2,533	109	2,388	-	-	-	-
Retained Earnings	-7.2%	-55,722	-52,000	-46,109	-41,060	-37,600	-33,740	-28,500	-17,055	-	-18,938	-8,709
Additional Paid-In Capital	2.7%	56,912	55,414	45,572	43,324	40,105	33,849	30,906	9,158	-	8,828	4,080
Shares Outstanding	0.9%	7,466	7,401	1,074	904	819	708	452	407	407	407	340
Float	-	-	-	-	4,100	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Cashflow From Operations	-18.4%	-3,100	-2,617	-2,331	-2,836	-2,983	-3,067	-1,571	-1,037	-394	-1,248	-1,506	-	-
Share Based Compensation	114.7%	1,513	705	1,065	1,265	2,171	3,041	1,047	149	181	225	272	-	-
Cashflow From Financing	-100.2%	-15.28	6,175	415	1,920	5,068	-594	7,126	-	-	-106	-60.78	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PXMD Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
General and administrative	$ 3,297,350	$ 3,814,184
Research and development	392,813	222,491
Total operating expenses	3,690,163	4,036,675
Loss from operations	(3,690,163)	(4,036,675)
Other income (expense)
Interest expense		(3,928)
Loss on extinguishment of debt		(36,850)
Change in fair value of notes		335,364
Other expense	(3,022)	(91,658)
Total other income (expense)	(3,022)	202,928
Net loss	$ (3,693,185)	$ (3,833,747)
Basic weighted average number of shares outstanding	7,418,281	743,373
Diluted weighted average number of shares outstanding	7,418,281	743,373
Basic net loss per share	$ (0.50)	$ (5.16)
Diluted net loss per share	$ (0.50)	$ (5.16)

PXMD Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash	$ 1,626,892	$ 4,710,642
Prepaid and other current assets	1,266,211	969,763
Total current assets	2,893,103	5,680,405
Total assets	2,893,103	5,680,405
Current liabilities
Accrued expenses	65,128	177,118
Accrued expenses - compensation		787,981
Total current liabilities	1,203,095	1,795,332
Deferred revenue	500,000	500,000
Total liabilities	1,703,095	2,295,332
Commitments and contingencies (Note 8)
Stockholders' Equity (Deficit)
Common stock, par value $0.0001; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 7,465,629 and 7,401,242 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	747	740
Additional paid-in capital	56,912,182	55,414,069
Accumulated deficit	(55,722,926)	(52,029,741)
Total stockholders' equity (deficit)	1,190,008	3,385,073
Total liabilities, and stockholders' equity (deficit)	2,893,103	5,680,405
Series X Preferred Stock
Stockholders' Equity (Deficit)
Preferred stock, par value $0.0001, 10,000,000 shares authorized: Series X preferred shares, 500,000 shares authorized as of March 31, 2024 and December 31, 2023; 45,567 shares issued and outstanding at March 31, 2024 and December 31, 2023	5	5
Excludes related party
Current liabilities
Accounts payable	$ 1,137,967	811,733
Related party
Current liabilities
Accounts payable		$ 18,500

About PaxMedica, Inc.

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company has a research collaboration with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

CEO	Mr. Howard J. Weisman
WEBSITE	paxmedica.com
INDUSTRY	Biotechnology
EMPLOYEES	3

PaxMedica, Inc. Frequently Asked Questions

What is the ticker symbol for PaxMedica, Inc.? What does PXMD stand for in stocks?

PXMD is the stock ticker symbol of PaxMedica, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PaxMedica, Inc. (PXMD)?

As of Fri May 17 2024, market cap of PaxMedica, Inc. is 1.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PXMD stock?

You can check PXMD's fair value in chart for subscribers.

What is the fair value of PXMD stock?

You can check PXMD's fair value in chart for subscribers. The fair value of PaxMedica, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PaxMedica, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PXMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PaxMedica, Inc. a good stock to buy?

The fair value guage provides a quick view whether PXMD is over valued or under valued. Whether PaxMedica, Inc. is cheap or expensive depends on the assumptions which impact PaxMedica, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PXMD.